Clinical characteristics of patients with MPN enrolled in the study
| . | Total (n = 219) . | AAb against IFNs . | P . | |
|---|---|---|---|---|
| Absent . | Present . | |||
| (n = 190) . | (n = 29) . | |||
| Median age at sampling, years (interquartile range) | 62 (52–71) | 62 (51–71) | 63 (55–77) | .227 |
| Female sex, n (%) | 113 (51.6) | 100 (52.6) | 13 (44.8) | .550 |
| MPN diagnosis, n (%) | ||||
| ET* | 101 (46.1) | 81 (42.6) | 20 (69.0) | .029 |
| PV | 76 (34.7) | 72 (37.9) | 4 (13.8) | |
| MF | 36 (16.5) | 31 (16.3) | 5 (17.2) | |
| MPN-U | 6 (2.7) | 6 (3.2) | 0 (0.0) | |
| Driver mutation, n (%) | ||||
| JAK2† | 163 (74.4) | 146 (76.8) | 17 (58.6) | .019 |
| CALR | 41 (18.7) | 34 (17.9) | 7 (24.1) | |
| MPL | 4 (1.9) | 4 (2.1) | 0 (0.0) | |
| Triple negative | 11 (5.0) | 6 (3.2) | 5 (17.2) | |
| Cytoreduction,‡n (%) | 167 (76.3) | 142 (74.7) | 25 (86.2) | .242 |
| Ruxolitinib, n (%) | 21 (9.6) | 15 (7.9) | 6 (20.7) | .036 |
| Concomitant autoimmune condition, n (%) | 24 (11) | 20 (10.6) | 4 (13.8) | .536 |
| SARS-CoV-2 infection, n (%) | 29 (13.2) | 25 (13.2) | 4 (13.8) | .900 |
| Hospitalization due to COVID-19, n (%)§ | 8/29 (27.6) | 6/25 (24) | 2/4 (50) | .300 |
| . | Total (n = 219) . | AAb against IFNs . | P . | |
|---|---|---|---|---|
| Absent . | Present . | |||
| (n = 190) . | (n = 29) . | |||
| Median age at sampling, years (interquartile range) | 62 (52–71) | 62 (51–71) | 63 (55–77) | .227 |
| Female sex, n (%) | 113 (51.6) | 100 (52.6) | 13 (44.8) | .550 |
| MPN diagnosis, n (%) | ||||
| ET* | 101 (46.1) | 81 (42.6) | 20 (69.0) | .029 |
| PV | 76 (34.7) | 72 (37.9) | 4 (13.8) | |
| MF | 36 (16.5) | 31 (16.3) | 5 (17.2) | |
| MPN-U | 6 (2.7) | 6 (3.2) | 0 (0.0) | |
| Driver mutation, n (%) | ||||
| JAK2† | 163 (74.4) | 146 (76.8) | 17 (58.6) | .019 |
| CALR | 41 (18.7) | 34 (17.9) | 7 (24.1) | |
| MPL | 4 (1.9) | 4 (2.1) | 0 (0.0) | |
| Triple negative | 11 (5.0) | 6 (3.2) | 5 (17.2) | |
| Cytoreduction,‡n (%) | 167 (76.3) | 142 (74.7) | 25 (86.2) | .242 |
| Ruxolitinib, n (%) | 21 (9.6) | 15 (7.9) | 6 (20.7) | .036 |
| Concomitant autoimmune condition, n (%) | 24 (11) | 20 (10.6) | 4 (13.8) | .536 |
| SARS-CoV-2 infection, n (%) | 29 (13.2) | 25 (13.2) | 4 (13.8) | .900 |
| Hospitalization due to COVID-19, n (%)§ | 8/29 (27.6) | 6/25 (24) | 2/4 (50) | .300 |
AAbs were observed more frequently in patients with ET compared with other Ph-negative MPN (P = .009).
AAbs were observed more frequently in patients without JAK2 mutation compared with patients with JAK2 V617F (P = .042).
Cytoreduction included hydroxyurea (139 cases), ruxolitinib (21 cases), and interferon (7 cases). Of note, none of the patients treated with IFN developed AAbs.
Percentage values refer to the 29 patients with SARS-CoV-2 infection.